Compare drug alternatives

Ajovy ® Alternatives

Ajovy ®(fremanezumab)
Vyepti®(eptinezumab)
Prescription Only
Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...
Prescription Only
Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...
Dosage & Administration
Administration
Subcutaneous. Learn more.
Intravenous Infusion. Learn more.
Dosing
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.
Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.
Latin Shorthand
225 mg/mo or 675 mg q3mo. Learn more.
100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
Patient specific maximum benefit.. Learn more.
$200 per infusion administration fee. Learn more.
Assistance Expiration
12/31/2023. Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.
The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.
CGRP Antagonist. Learn more.
Special Populations
Is there a pregnancy exposure registry for AJOVY?

Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.

What is the risk associated with the use of AJOVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development.

What is the estimated background risk of major birth defects and miscarriage for the indicated population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine.

Is AJOVY safe to use during lactation?

There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition.

Is AJOVY safe and effective for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is there any information on the use of AJOVY in geriatric patients?

Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Is it safe to use VYEPTI during pregnancy?

There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy.

Are there any risks to the fetus if the mother receives VYEPTI?

Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively.

Is it safe to breastfeed while using VYEPTI?

There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding.

Is VYEPTI safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients.

Is VYEPTI safe for use in geriatric patients?

Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.